Evolva participates in food ingredient research initiative
Evolva Holding SA announced that its Danish subsidiary has commenced a research initiative focusing on novel ways to produce vanillin and arabinogalactan proteins. Together with Evolva, the initiative includes four Danish research groups from the University of Copenhagen and the Danish Technical University, Danisco, and the Lawrence Berkeley National Laboratory, a major US research institution.
The purpose of the project is to establish microbial cell factories for production of these ingredients by fermentation. Evolva aims to find approaches for a commercially viable and environmentally acceptable production of vanillin as part of the application of its technologies to “white” biotechnology. The research initiative is supported by a grant from the Danish Council for Strategic Research.
Evolva’s share of the total research grant will amount to approximately CHF 0.7 million. The program is expected to run for four years.
Neil Goldsmith, CEO of Evolva Holding SA, said “Through our Danish operation’s participation in this research initiative we aim to further demonstrate the versatility of our technology platform, which has applications in many business sectors. We are pleased to be part of this distinguished group of collaborators and are confident we will make a significant contribution to this project. The biosynthetic pathways leading to vanillin also have important pharmaceutical potential, and hence the project has dual-use relevance for Evolva.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
Artificial intelligence for better diagnostics - Standardized methods facilitate the evaluation of Raman spectra
New technique shows in detail where drug molecules hit their targets in the body - The new method could speed the development of many new drugs
ChondroGene published paper ´Human genome project and cardiovascular disease genes´ - In landmark textbook ´Molecular Basis of Cardiovascular Disease´
CV Therapeutics Appoints Joseph M. Davie, M.D., Ph.D. to Board of Directors
ProtAffin AG appoints Dr. Simon Moroney to Supervisory Board
PerkinElmer Life Sciences Introduces Protein S-Nitrosylation Detection Technology - New NitroGlo(TM) Detection Kit Offers New Capabilities for Neurobiology Researchers
EPEMED the European Personalised Medicine association appoints its General Delegate and several new board members
